St. Jude Medical beats guidance with Q4 prelims
St. Jude Medical says its preliminary results for the 4th quarter beat the high end of its prior forecast.
St. Jude Medical said it's likely to top the high end of its 4th-quarter outlook for both sales and earnings, predicting 4% revenue growth and a bottom-line gain of as much as 154% for the 3 months ended Dec. 28, 2013, compared with the same period in 2012.
St. Jude forecast preliminary earnings per share of 97¢-99¢ on sales of $1.42 billion for the quarter, with adjusted EPS excluding 1-time items of $1.52-$1.54.
Prior guidance called for 4th-quarter adjusted EPS of 95¢-97¢ on sales of $1.32 billion to $1.40 billion.